drugset / Trial / NCT04612673
A Phase II Study of Anti-PD-1 Antibody, Sintilimab, as Second-line Therapy for Biomarker-selected Advanced or Metastatic NSCLC
Phase 2
Unknown
33 enrolled
China Medical University, China
Anshan Tumor Hospital · collabBenxi Cental Hospital · collabLiaoning Cancer Hospital & Institute · collabShengjing Hospital · collabThe First Affiliated Hospital of Dalian Medical University · collabThe First People's Hospital of Jingzhou · collabThe People's Hospital of Liaoning Province · collabThe Second Affiliated Hospital of Dalian Medical University · collab
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to to explore the efficacy and safety of PD-1 immune check point inhibitor, sintilimab, in biomarker-selected subjects with advanced or metastatic Non-small Cell Lung Cancer who have failed from standard front-line treatment.
Timeline
- Start
- 2020-11-20
- Primary completion
- 2022-06-30
- Completion
- 2022-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Sintilimab | Monoclonal antibody | 200 mg | Intravenous |